OLAPARIB TABLET 150 MG

Olaparib Tablet 150 mg is an oral targeted anticancer medication used in the treatment of multiple BRCA-mutated cancers, including ovarian, breast, pancreatic, and prostate cancer. It belongs to a specialized class of medicines designed to attack cancer cells at the molecular level while minimizing damage to healthy cells.

Olaparib is classified as a PARP (poly ADP-ribose polymerase) inhibitor, which works by blocking the DNA repair mechanism in cancer cells. By preventing damaged DNA from being repaired, olaparib causes cancer cells to accumulate genetic damage, ultimately leading to cancer cell death and slowing disease progression.

Olaparib 150 mg Tablet is taken orally and must be used strictly under the supervision of an oncologist. It is a proven targeted therapy option for patients with confirmed BRCA gene mutations and plays a key role in modern precision cancer treatment strategies.

Product Feature

• Oral PARP inhibitor targeted therapy
• Contains Olaparib 150 mg
• Effective in BRCA-mutated cancers
• Used as maintenance and advanced cancer therapy
• Twice-daily dosing (as prescribed)
• High bioavailability oral formulation
• Manufactured under GMP-compliant standards
• Prescription-required oncology medicine

How It Helps

• Blocks PARP enzymes required for DNA repair in cancer cells
• Causes accumulation of DNA damage, leading to cancer cell death
• Helps slow disease progression in BRCA-mutated ovarian, breast, pancreatic, and prostate cancers
• Supports maintenance therapy to reduce the risk of cancer recurrence
• Provides convenient oral targeted treatment under an oncologist’s supervision